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The diagnosis of valvular heart disease is a difficult 
problem in everyday clinical practice. There is a wide 
spectrum of presentation – in some cases murmurs 
are found incidentally and in others, patients present 
very late with dire haemodynamic consequences 
of neglected valve lesions that may preclude them from definitive 
surgery. This review serves as a guide to the primary care clinician in 
the diagnosis and management of valve disease.
With the decline in rheumatic heart disease and the ageing 
population in the developed world, there has been a change in the 
disease patterns of valve lesions over the last few decades. Western 
populations are experiencing greater numbers of degenerative valve 
disease. In the developing world, however, rheumatic heart disease 
remains an important cause of valve pathology. Sliwa et al.,[1] in 
the Heart of Soweto Study, showed an incidence of new cases of 
rheumatic heart disease of 23.5/100 000 cases per annum. 
Clinical evaluation (history and examination) remains the corner­
stone of screening for valve pathology. An electrocardiogram (ECG) 
and a chest radiograph (CXR) are seen as important adjuncts to 
clinical evaluation and may provide important diagnostic clues to 
confirming pathology.
Echocardiography with colour flow and Doppler (not focus­
assessed transthoracic echocardiography (FATE) scans) plays a pivo­
tal role in confirming the diagnosis, and assessing the severity of the 
valve lesions and concomitant pulmonary hypertension, other valve 
lesions and haemodynamic consequences. 
Invasive testing with cardiac catheterisation is reserved for patients 
in whom there is a discrepancy between clinical findings and 
echocardiography.
Mitral stenosis
Mitral stenosis (MS) is almost exclusively caused by chronic rheumatic 
heart disease. The rheumatic process leads to inflammation, resulting 
in commissural fusion, thickening and fibrosis of both the leaflets and 
subvalvular apparatus. Fewer than half of patients with MS recollect 
an episode of acute rheumatic fever. Other rare causes of mitral 
valve (MV) obstruction include congenital MS, degenerative mitral 
annular calcification, atrial myxomas, large thrombus or vegetations, 
systemic lupus erythematosus (SLE) and carcinoid syndrome. 
A normal MV area is 4 ­ 6 cm2. During diastole, the MV opens 
to allow the unobstructed flow of blood into the left ventricle. With 
MS, there is obstruction to ventricular inflow; the resultant pressure 
gradient causes an increase in left atrial (LA) pressure. Pulmonary 
oedema usually occurs secondary to this rise in pressure.
Any condition that increases heart rate, including sepsis, thyroid 
disease, anaemia, atrial fibrillation (AF) and pregnancy, may precipi­
tate symptoms. 
Clinical features and special investigation findings are described 
in Table 1.[2]
Patients with mild disease and symptoms may require diuretic 
therapy and sodium restriction to reduce congestion. Beta­blockers 
are often prescribed, the rationale being that reducing the heart rate 
increases diastolic filling time, reduces the gradient and improves 
effort tolerance. It is generally used in patients with Class II ­ III 
symptoms. There is no evidence for its prognostic benefit or use in 
multivalve disease.[2]
Verapamil may also be used for heart rate control, but should 
not be administered concomitantly with beta­blockers. There is 
no benefit from the use of angiotensin­converting enzyme (ACE) 
inhibitors. Digoxin may be used for heart rate control in patients with 
AF, but is otherwise contraindicated. 
Anticoagulation with vitamin K antagonists (warfarin) is advised in 
patients with previous embolic events, clot in the LA or AF (regardless 
of the presence of LA clot). Aspirin is not used, as its benefit in stroke 
prevention is low, with a similar bleeding risk to warfarin. The CHADS 
or CHADS­VASc score should not be applied to patients with MV 
disease and AF, as the stroke risk is already high; these patients should 
be anticoagulated. The new oral anticoagulants have not been tested in 
this setting and should not be used.
For patients with moderate to severe disease or for those with an 
episode of acute pulmonary oedema, definitive surgical treatment 
should be considered and they should be referred for evaluation. 
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Percutaneous balloon mitral valvuloplasty has superseded surgical 
valvotomy (closed and open) for patients with pliable valves.[3] This 
is also the treatment of choice for pregnant MS patients with pliable 
valves and poor response to medical therapy. Those with calcified, 
non­pliable valves or significant concomitant mitral regurgitation 
(MR) are referred for valve replacement surgery.
Mitral regurgitation
MR may be classified depending on the clinical presentation (acute or 
chronic) or leaflet pathology (functional versus organic).
Acute MR is a medical emergency presenting with acute pulmonary 
oedema and hypotension and is usually caused by endocarditis, 
myocardial infarction with papillary muscle rupture or spontaneous 
rupture of the chordae. Afterload reduction with intravenous nitrates 
or nitroprusside and early surgical intervention is usually required.
The clinical and investigational features of chronic MR are 
summarised in Table 2. Signs of severity include clinical features of 
heart failure, pulmonary hypertension, a loud murmur grade ≥3/6 
and presence of a third heart sound in the absence of heart failure.
Functional MR is characterised by normal leaflets and is secondary to 
a dilated and dysfunctional left ventricle. Echocardiography is required 
to accurately confirm this diagnosis and may differentiate ischaemic 
from non­ischaemic causes. Functional MR requires optimisation of 
heart failure therapy, whereas moderate or severe ischaemic MR may 
require surgery with possible coronary revascularisation.
Organic MR refers to primary leaflet abnormality resulting in MR. The 
cause is most often rheumatic in South African (SA) patients, whereas 
degenerative or myxomatous disease is most common in the developed 
world. Other causes include fibro­elastic disease, congenital (isolated cleft 
or atrioventricular (AV) canal defect), Mar fan syndrome and endocarditis.
Medical therapy has been shown not to be of benefit in MR. 
Indications for surgery include symptoms, development of AF, 
pulmonary hypertension, end­systolic diameter >40 mm and ejection 
fraction <60% on echocardiography. Surgical options include MV 
replacement or repair, which may mandate earlier surgery, provided 
a successful durable repair can be obtained.
Aortic stenosis
Aortic stenosis (AS) is the most common valve lesion in western 
countries and mainly a disease of the elderly. Common causes of AS 
include: 
• degenerative trileaflet AS
• degenerative bicuspid AS
• rheumatic heart disease – there would usually be concomitant MV
•  disease
• other (rare): congenital AS, Paget’s disease, end­stage kidney disease, 
chronic inflammatory diseases.
Haemodynamically significant obstruction usually occurs when 
the valve area is <1 cm2. Left ventricular hypertrophy develops in 
response to the progressive obstruction. Risk factors for degenerative 
AS are similar to those for atherosclerosis, i.e. hypertension, diabetes, 
dyslipidaemia and smoking.
Table 1. Clinical and special investigation features of mitral stenosis
Mitral stenosis
History
Exertional dyspnoea
Orthopnoea
Paroxysmal nocturnal dyspnoea
Acute frank pulmonary oedema
Haemoptysis
Embolism: 20 ­ 25%, especially cerebral
Chest discomfort
Hoarseness: Ortner’s syndrome
Physical findings
Normal character, small volume pulse in severe MS
Irregularly irregular pulse: atrial fibrillation
 JVP may be elevated: prominent cv wave if concomitant 
significant TR
Undisplaced, tapping apex beat
Loud first heart sound
Loud pulmonary component of S2 if pulmonary hypertension
Opening snap after S2, if pliable valve
The closer to S2, the more severe the MS
Low­pitched mid­diastolic murmur
Best heard at the apex
Longer murmur = more severe MS
 If patient is in sinus rhythm, presystolic accentuation of the 
murmur may be audible
Pulmonary crepitations at lung bases
 Other associated valve lesions: mitral regurgitation, tricuspid 
disease, aortic disease
Special investigations
ECG 
Usually unremarkable 
 In sinus rhythm, LA enlargement: broad P wave in lead II or 
a predominantly negative deflection in lead V1 
In AF, no comment on LA size can be made 
CXR
Normal­sized heart (ventricle) 
Upper­lobe blood diversion/interstitial oedema
Enlarged LA seen by:
   Straight left heart border
   Splaying on the coryna
   Double shadow on the right heart silhouette
JVP = jugular venous pressure; TR = tricuspid regurgitation; MS = mitral stenosis; 
LA = left atrial; AF = atrial fibrillation.
Table 2. Clinical and special investigation features of mitral 
regurgitation
Mitral regurgitation
History
 Heart failure symptoms (dyspnoea, paroxysmal nocturnal 
dyspnoea, orthopnoea)
Leg swelling
Physical findings
Displaced, volume­loaded apex beat
Soft S1
Pan­systolic murmur at apex, radiating to axilla
Third heart sound
Special investigations
ECG
Usually unremarkable
 The presence of abnormal QRS complexes eludes to underlying 
myocardial pathology rather than primary isolated mitral valve 
pathology 
CXR
Cardiomegaly
Upper­lobe blood diversion/interstitial oedema
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Patients are asymptomatic for many years. Once symptoms occur, 
however, there is a rapid decline in life expectancy.[4]
Clinical features of AS are shown in Table 3. 
There is no place for medical management of patients with symp­
tomatic AS. It is a mechanical obstruction for which the definitive 
treatment is aortic valve replacement. These patients should therefore 
all be referred promptly for assessment for valve replacement 
surgery,[5] which prolongs and improves quality of life, even in 
octogenarians.[6] For those in whom the risk of surgery is too high, 
transcatheter aortic valve replacement is currently a possibility.[7] 
Aortic regurgitation
Aortic regurgitation may occur as a result of leaflet pathology or 
secondary to aortic root pathology. Acute regurgitation is poorly 
tolerated and constitutes a medical and surgical emergency. It is 
commonly caused by infective endocarditis or aortic root dissection. 
Chronic regurgitation is well tolerated and patients are often 
asymptomatic for many years. Common causes of primary valve 
lesions are rheumatic heart disease, infective endocarditis, congenital 
bicuspid valves, and rheumatoid arthritis. Conditions primarily 
affecting the root, and hence causing regurgitation, are Marfan’s 
syndrome, syphilis, sero­negative spondyloarthritides, aortic dis­
section and osteogenesis imperfecta.
The clinical features are summarised in Table 4. Symptomatic 
aortic regurgitation requires referral for the assessment for aortic 
valve replacement. There is no place for medical therapy outside of it 
being a bridge to surgery or in those too ill for surgery.[2,8­10]
Tricuspid valve disease
Tricuspid stenosis (TS) is rare and usually rheumatic in origin.[11] Most 
patients with rheumatic tricuspid valve (TV) disease present with 
tricuspid regurgitation (TR) or a combination of TR and TS. Isolated 
rheumatic TS is uncommon, but usually accompanies MV disease. 
Less common and unusual causes of obstruction to right atrial (RA) 
emptying include congenital tricuspid atresia, RA tumours, carcinoid 
syndrome, endomyocardial fibrosis, TV vegetations, pacemaker leads 
or extracardiac tumours.[11] TS is found at autopsy in 15% of patients 
with rheumatic heart disease, but is of clinical significance in <5%. 
As is the case with MS, TS is more common in women. The RA is 
usually dilated in TS. Clinical and special investigation findings in TS 
are presented in Table 5.
The most common cause of TR is a dilated right ventricle (RV) and TV 
annulus (‘functional TR’).[12] Functional TR may follow on pulmonary 
hypertension and its causes, RV obstruction (e.g. pulmonary stenosis) 
or intrinsic RV abnormality (e.g. RV infarction). Rheumatic TR is rare. 
Non­rheumatic, valvular causes of TR include infective endocarditis, 
Ebstein anomaly, TV prolapse, carcinoid syndrome, trauma, papillary 
muscle dysfunction, and connective tissue disease. The clinical and 
imaging features of TR are listed in Table 5.[11­13]
Prosthetic valves 
There are two types of prosthetic valves: mechanical valves and 
bioprosthetic (tissue) valves. The major differences between the two 
relate to risk of thromboembolism (higher with mechanical valves) 
and structural deterioration (higher with bioprostheses).[14] Mechanical 
valves are classified into three groups: bileaflet, tilting disc and ball­
cage. Bileaflet mechanical valves are most commonly implanted. 
Patients with mechanical valves require long­term anticoagulation. 
The risk of thromboembolism is about 6 times higher without 
anticoagulants, and the risk of de novo valve thrombosis is also 
Table 3. Clinical and special investigation features of aortic stenosis
Aortic stenosis
History
Exertional dyspnoea
Angina
Syncope
Physical findings
Small­volume, slow­rising pulses
Narrow pulse pressure
JVP normal, unless heart failure or MV disease
Pressure­loaded undisplaced apex beat
Soft or single second heart sound
 Crescendo­decrescendo ejection systolic murmur at base of 
the heart
Radiated to carotids
Longer murmur = more severe
 High­pitched widely radiating murmur: Gallavardin effect – can 
be mistaken for MR
Systolic click in bicuspid valve may be heard
Special investigations
ECG
Left ventricular hypertrophy
CXR
Normal­sized heart (ventricle) 
Aortic calcification
Post­stenotic dilatation: especially in bicuspid valves
Table 4. Clinical and special investigation features of aortic 
regurgitation
Aortic regurgitation
History
Long asymptomatic period
Dyspnoea 
Orthopnoea
Paroxysmal nocturnal dyspnoea
Nocturnal angina
Physical findings
Collapsing pulses
 Wide pulse pressure (difference between systolic and diastolic is 
>50% of the systolic pressure)
Duroziez sign
 Heart failure signs: elevated JVP, leg swelling, crepitations at 
lung bases
Volume­loaded, displaced apex
Early diastolic murmur at base of heart
Best heard with patient sitting forward, in end­expiration
Longer murmur = more severe
A systolic murmur (due to increased flow or concomitant AS)
An Austin­Flint murmur (late diastolic apical murmur)
Special investigations
ECG
No specific diagnostic changes
 Occasionally in severe AR­left ventricular hypertrophy, and 
left axis deviation may be seen
CXR
Cardiomegaly
Pulmonary congestion
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higher. Warfarin is the anticoagulant of choice and the international 
normalised ratio should be between 2.5 and 3.5. Antiplatelet agents 
such as aspirin do not provide adequate protection and are not 
recommended without the use of anticoagulants. 
Bioprostheses were developed to overcome the challenges of 
long­term anticoagulation and increased risk of thromboembolism 
associated with mechanical valves. A stented tissue valve consists 
of three tissue leaflets mounted on a ring with semi­rigid stents 
that facilitate implantation. Because stents add to obstruction and 
increase stress on the leaflets, stentless tissue valves were developed 
for the aortic position and are particularly useful for patients with 
small aortic roots. More recently, a transcatheter bioprosthesis 
has been developed, which can be implanted via a catheter at the 
aortic valve position.[15] Homograft aortic valves are harvested from 
cadavers, sterilised with antibiotics and cryopreserved at −196° 
for long periods before implantation. Pulmonary autografts (Ross 
procedure) involve removal of a patient’s native pulmonary valve and 
reimplantation to replace the diseased aortic valve.[15]
Conclusion
The clinical evaluation remains essential in establishing a diagnosis in 
patients presenting with heart failure due to valvular heart disease. Awaiting 
results of special investigations should not hinder timeous referral. Those 
with symptomatic valvular heart disease should be referred promptly for 
specialist evaluation with a view to definitive surgical correction. 
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Table 5. Clinical and special investigation features of tricuspid valve disease
Tricuspid stenosis Tricuspid regurgitation
History
Progressive fatigue, oedema, anorexia
Minimal orthopnoea and paroxysmal nocturnal dyspnoea
Pulmonary oedema and haemoptysis are rare
History
Well tolerated in absence of pulmonary hypertension, often asymptomatic
 Right heart failure (swollen abdomen, swelling of legs and painful, congestive
enlargement of liver)
Throbbing pulsations in the neck (from elevated JVP) and eyeballs
Physical findings
 Diastolic rumble at lower left sternal border, increasing in intensity 
with inspiration
Often confused with mitral stenosis
Neck vein distention, with prominent a waves 
Absent right ventricular lift/heave
Hepatic pulsation
Ascites, peripheral oedema
Associated murmurs of mitral and aortic valve disease
Physical findings
Weight loss, cachexia, cyanosis and jaundice
AF is common
Elevated JVP with prominent cv waves
Venous systolic thrill and murmur in neck
Tender hepatomegaly
S3 gallop originating from RV
Loud P2 and parasternal heave if pulmonary hypertension present
Pansystolic murmur of TR
Special investigations
ECG
Tall right atrial P waves and no RV hypertrophy
CXR
Dilated RA without enlarged pulmonary artery segment
Special investigations
ECG
Usually nonspecific; incomplete RBBB, Q waves in V1, AF are common
CXR
Marked cardiomegaly
